SkyQuest Technology Group recently introduced Generic Drugs Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Generic Drugs Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Global Generic Drugs Market size was valued at USD 487.21 billion in 2023 and is poised to grow from USD 513.03 billion in 2024 to USD 775.48 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).
Generic drugs are similar in chemical composition to their reference branded drugs however they are cheaper which makes them more attainable than the brand-name medications. The increasing incidence of chronic diseases has enhanced the need for low-cost drugs, particularly driving the generic drug market. Cost advantage in comparison to the branded counterparts is a key factor contributing to its adoption in developing and developed economies.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/generic-drugs-market
The FDA grants patent and exclusivity protection to the developer of the branded drug to be able to benefit from their research and innovation for a period of a few years. During this period there are too many competitors for the brand and no generic products can enter the generic drug market. However, once the patent has expired generic drugs can enter the market through a fast-track FDA approval process. Generic medications must meet the same quality, safety, and efficiency standards as branded ones. Moreover, the expirations of expiring patents of high value drugs have led to an increase in the development of generic drugs, which also drives generic drug market growth.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Generic Drugs Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Route of Administration
Oral, Parenteral, Topical, Inhalation, Transdermal, Ophthalmic, Others
Therapeutic Application
Cardiovascular Disorders, Central Nervous System (CNS) Disorders, Infectious Diseases, Oncology, Respiratory Diseases, Gastrointestinal Disorders, Endocrine Disorders, Others
Formulation
Solid Dosage Forms, Liquid Dosage Forms, Semi-solid Forms, Gaseous Forms
Distribution Channel
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores, Wholesalers & Distributors
End User
Hospitals, Clinics, Ambulatory Surgical Centers (ASCs), Retail Consumers
Generic Drugs Market – Regional Analysis:
– Generic Drugs North America Market includes (Canada, Mexico, USA)
– Generic Drugs Europe Market includes (Germany, France, Great Britain, Italy, Spain, Russia)
– Generic Drugs Asia-Pacific Market includes (China, Japan, India, South Korea, Australia)
– Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa)
– Generic Drugs South America Market includes (Brazil, Argentina)
– Generic Drugs Oceania Market (Australia & New Zealand)
Top Market Players in Generic Drugs Market are:
Sandoz – Switzerland
Teva Pharmaceuticals – Israel
Sun Pharmaceutical Industries Ltd. – India
Viatris Inc. – USA
Fresenius Kabi AG – Germany
Cipla Ltd. – India
Dr. Reddy’s Laboratories Ltd. – India
Lupin Limited – India
Aspen Pharmacare Holdings Limited – South Africa
Zydus Cadila – India
KRKA d.d. – Slovenia
Towa Pharmaceutical Co., Ltd. – Japan
STADA Arzneimittel AG – Germany
Glenmark Pharmaceuticals Ltd. – India
Amneal Pharmaceuticals, Inc. – USA
Biocon Limited – India
Aurobindo Pharma Ltd. – India
Sawai Pharmaceutical Co., Ltd. – Japan
Torrent Pharmaceuticals Ltd. – India
Hikma Pharmaceuticals PLC – UK
Generic Drugs Market Recent Developments:
In June 2024, Teva Pharmaceuticals introduced the US-licensed generic of Victoza, which is liraglutide injection 1.8mg. It is used to treat type 2 diabetes and works to control blood sugar levels and reduces the possibility of strokes and cardiovascular diseases.
In May 2024, Novartis strengthened its pipelined portfolio of radioligand therapy by acquiring Mariana Oncology, which is a US-based biotech firm specializing in radioligand therapy. It also got various radio ligand therapy programs and the preclinical phase of the technology.
Also Read –
https://www.skyquestt.com/report/craft-spirits-market
https://www.skyquestt.com/report/aggregates-market
Forward-Looking Insights
The Generic Drugs Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
